Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

End-of-day quote. End-of-day quote  - 10/26
3236 INR   +1.19%
06:19p DR REDDY LABORA : Reddys Q2 net down 60% on poor showing in North Am..
03:59p DR REDDY LABORA : Announces New Strategic Deal with Gland Pharma in ..
10/25 DR REDDY LABORA : Doctor Reddy's posts 2Q profit
News SummaryMost relevantAll newsSector news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
06:19p DR REDDY LABORATORIES : Reddys Q2 net down 60% on poor showing in North America,..
03:59p DR REDDY LABORATORIES : Announces New Strategic Deal with Gland Pharma in the U...
10/25 DR REDDY LABORATORIES : Doctor Reddy's posts 2Q profit
10/25 DR REDDY LABORATORIES : . Reddy’s Q2 and H1 FY17 Financial Results
10/25 DR REDDY LABORATORIES : Reddys Laboratories Q2 net profit at Rs 309 crore; EBITD..
10/25 DR REDDY LABORATORIES : . Reddy’s Q2 and H1 FY17 Financial Results
10/14 DR REDDY LABORATORIES : . Reddy's to Release Q2 FY17 Results on Oct 25, 2016; Ea..
10/14 DR REDDY LABORATORIES : .Reddy's Lab launches Lamotrigine Orally Disintegrating ..
10/14 DR REDDY LABORATORIES : Sells aripiprazole in us
10/13 DR REDDY LABORATORIES : Announces the Launch of Aripiprazole Tablets, USP Tablet..
More news
Sector news : Pharmaceuticals - NEC
04:13p GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
04:05pDJGlaxo Profit Jumps on Weaker Pound
09:08a Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:23a Dr. Reddy's teams up with Gland Pharma to market injectable generics in U.S.
10:01a Dr. Reddy's Laboratories Limited 2017 Q2 - Results - Earnings Call Slides
10/25 Dr. Reddy's Laboratories' (RDY) Q2 2017 Results - Earnings Call Transcript
10/25 Dr.Reddy's Laboratories revenues off 10% in FQ2
10/25 Dr. Reddy's reports FQ2 results
Financials ( INR)
Sales 2017 149 943 M
EBIT 2017 19 036 M
Net income 2017 17 399 M
Debt 2017 12 161 M
Yield 2017 0,58%
P/E ratio 2017 31,20
P/E ratio 2018 21,25
EV / Sales 2017 3,73x
EV / Sales 2018 3,21x
Capitalization 546 409 M
More Financials
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 45
Average target price 3 165  INR
Spread / Average Target -1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.94%311 781
ROCHE HOLDING LTD.-16.53%198 222
PFIZER INC.0.00%195 799
NOVARTIS AG-14.06%191 921
MERCK & CO., INC.17.29%171 305
More Results